Barclays Maintains Overweight on AbbVie, Lowers Price Target to $187

AbbVie, Inc. +0.22%

AbbVie, Inc.

ABBV

170.28

+0.22%

Barclays analyst Carter Gould maintains AbbVie (NYSE: ABBV) with a Overweight and lowers the price target from $195 to $187.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via